IQVIA Holdings Earnings Call Highlights Growth And AI

IQVIA Holdings ((IQV)) has held its Q1 earnings call. Read on for the main highlights of the call.

IQVIA’s latest earnings call struck an upbeat tone, highlighting record revenue, an earnings beat and accelerating organic growth across both Commercial and R&D segments. Management acknowledged modest margin pressure, a soft-looking book‑to‑bill ratio and elevated leverage, but framed these as mix and currency driven rather than signs of weakening demand.

Record Q1 Revenue and EPS Beat

IQVIA reported Q1 revenue of $4.151 billion, up 8.4% year over year, or 6.0% in constant currency, marking a new high for the company. Adjusted diluted EPS rose 7.4% to $2.90, topping the high end of guidance and underscoring strong execution despite FX and mix headwinds.

Segment Revenue Strength

Commercial Solutions led the quarter with revenue of $1.754 billion, up 11.6% reported and 8.5% in constant currency, reflecting robust demand for data and technology. R&D Solutions delivered $2.397 billion, up 6.2% reported and 4.2% in constant currency, supported by healthy trial activity and services growth.

Adjusted EBITDA and Cash Generation

Adjusted EBITDA climbed 5.5% to $932 million, while adjusted net income reached $492 million, reinforcing IQVIA’s profit profile. Free cash flow jumped 15% to $491 million, equaling 100% of adjusted net income, giving the company ample flexibility for buybacks and investment.

Strong Bookings and Expanding Backlog

R&D Solutions net new bookings hit $2.5 billion, a double‑digit increase that points to sustained demand from biopharma clients. Total backlog grew to $34.2 billion, with $8.9 billion expected to convert over the next 12 months, providing good revenue visibility and underpinning the growth outlook.

Raised and Reaffirmed Full‑Year Guidance

Management reaffirmed full‑year 2026 revenue guidance of $17.15 billion to $17.35 billion and adjusted EBITDA of $4.05 billion to $4.25 billion, signaling confidence in the pipeline. They also raised adjusted diluted EPS guidance to a range of $12.65 to $12.95, implying solid mid‑ to high‑single‑digit earnings growth.

Solid Q2 Outlook

For Q2, IQVIA guided revenue to $4.28 billion to $4.34 billion, implying 6.5% to 8.0% growth versus last year. Adjusted EBITDA is expected between $955 million and $975 million and adjusted diluted EPS between $2.98 and $3.08, keeping the company on a steady upward trajectory.

Rapid AI Progress and Adoption

Management spotlighted AI as a major growth catalyst, unveiling the iqvia.ai platform and deploying 192 AI agents across 64 use cases. Nineteen of the top 20 pharma companies are already using these agents, and the technology is helping drive stronger client demand and larger deal pipelines.

Strategic Wins and Partnerships

The quarter saw multiple high‑profile client wins, including a regional promotion pact with Pfizer across 23 European countries and a global intelligence collaboration with Boehringer Ingelheim in 59 countries. Additional AI‑enabled clinical and safety wins, plus a partnership in obesity research, underline IQVIA’s strategic positioning with big pharma.

Share Repurchases and Liquidity

IQVIA repurchased $552 million of its own shares in Q1, signaling management’s confidence in the valuation and cash‑flow durability. The company ended the quarter with $1.947 billion in cash and equivalents and still has about $1.2 billion remaining under its repurchase authorization.

Acceleration in Organic Growth

Underlying momentum improved, with Commercial Solutions organic growth accelerating to about 5%, roughly double last year’s pace. R&D Solutions organic growth reached about 3%, roughly triple last year, suggesting that demand is strengthening beyond the headline boost from FX and M&A.

Impact of Unusually Low Pass‑Throughs

Pass‑through bookings were about one‑third below historical norms, reflecting a mix shift in full‑service trials rather than softer demand. This reduced pass‑through contribution and pulled down the reported book‑to‑bill ratio to 1.04, making the metric appear weaker than underlying service‑fee activity.

Margin Pressure from FX and Mix

Adjusted EBITDA margin contracted by about 60 basis points in Q1, but management tied this to adverse foreign exchange and lower pass‑through mix. They emphasized that core operations remain solid, with pricing, utilization and project performance holding up despite the reported margin dip.

Leverage and Balance Sheet Considerations

Gross debt stood at $15.833 billion and net debt at $13.886 billion, leaving net leverage at 3.62 times trailing adjusted EBITDA. While manageable for a recurring‑revenue model, that level may attract investor scrutiny, especially alongside aggressive buybacks and rising interest costs.

Timing Risk from Funding to Awards

Management highlighted that while funding in evidence‑based platforms nearly doubled, there is typically a 12 to 18‑month lag before this turns into awards and revenue. They also noted that sponsor decision speeds are not yet back to pre‑disruption norms, which could cause uneven conversion timing quarter to quarter.

FX Tailwinds Likely to Fade

The company benefited from favorable FX in Q1, boosting reported growth and profit metrics relative to constant‑currency rates. Management expects those tailwinds to moderate as the year progresses, which means reported growth could edge closer to underlying constant‑currency performance.

Guidance and Forward‑Looking View

IQVIA’s outlook remains constructive, with full‑year 2026 revenue and EBITDA guidance reaffirmed and EPS guidance raised, supported by robust backlog and AI‑driven demand. Q2 guidance implies continued mid‑ to high‑single‑digit growth across revenue, EBITDA and EPS, assuming current currency levels hold through year‑end.

IQVIA’s earnings call painted a picture of a company leaning into secular tailwinds in data, technology and AI while managing around FX, mix and leverage issues. For investors, the combination of record revenue, accelerating organic growth, rising EPS guidance and strong bookings suggests the growth story remains very much intact, albeit with some macro‑driven noise in the near term.